10.59
+0.23
+(2.26%)
As of 3:55:19 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 7 |
| Avg. Estimate | 687.5k | 687.5k | 2.75M | 285.71k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 5M | 5M | 20M | 2M |
| Year Ago Sales | 5.84M | 33.45M | 38.91M | 2.75M |
| Sales Growth (year/est) | -88.23% | -97.94% | -92.93% | -89.61% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.42 | -0.09 | -0.55 | -0.83 |
| EPS Actual | -0.8 | 0.64 | -0.42 | -0.59 |
| Difference | 0.62 | 0.73 | 0.13 | 0.23 |
| Surprise % | 43.33% | 770.53% | 23.09% | 28.13% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RNAC | -- | -- | -- | -- |
| S&P 500 | 6.40% | 6.07% | 9.36% | 14.28% |
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/9/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/9/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/14/2025 |
| Reiterates | Needham: Buy to Buy | 3/13/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/28/2025 |
| Reiterates | Needham: Buy to Buy | 1/27/2025 |
Related Tickers
TRML Tourmaline Bio, Inc.
13.05
+7.85%
MLTX MoonLake Immunotherapeutics
34.93
+2.83%
APGE Apogee Therapeutics, Inc.
31.14
+4.01%
IRON Disc Medicine, Inc.
38.72
+9.91%
SYRE Spyre Therapeutics, Inc.
12.19
+2.18%
KYTX Kyverna Therapeutics, Inc.
2.0250
+8.29%
RLYB Rallybio Corporation
0.2530
+0.96%
DYN Dyne Therapeutics, Inc.
7.05
+0.93%
CABA Cabaletta Bio, Inc.
1.2150
+11.47%
PRAX Praxis Precision Medicines, Inc.
29.65
+4.14%